Filing Details

Accession Number:
0001209191-21-025942
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-07 18:00:25
Reporting Period:
2021-04-05
Accepted Time:
2021-04-07 18:00:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1655759 Arvinas Inc. ARVN Pharmaceutical Preparations (2834) 472566120
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1753281 Ian Taylor C/O Arvinas, Inc.
5 Science Park, 395 Winchester Ave.
New Haven CT 06511
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-04-05 25,000 $16.00 103,645 No 4 M Direct
Common Stock Disposition 2021-04-05 4,100 $66.01 99,545 No 4 S Direct
Common Stock Disposition 2021-04-05 16,450 $66.80 83,095 No 4 S Direct
Common Stock Disposition 2021-04-05 4,450 $67.56 78,645 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-04-05 9,211 $0.00 9,211 $16.00
Common Stock Stock Option (right to buy) Disposition 2021-04-05 15,789 $0.00 15,789 $16.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2028-09-25 No 4 M Direct
28,601 2028-09-25 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.30 to $66.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.31 to $67.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.31 to $68.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  5. This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of June 1, 2017, with the remainder of the shares vesting in equal monthly installments following June 1, 2017 through June 1, 2020.
  6. This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested on June 28, 2019, with the remainder of the shares vesting in equal monthly installments following June 28, 2019 through June 28, 2022.